m6A-centered Crosstalk Information

Mechanism of Crosstalk between m6A Modification and Epigenetic Regulation
Crosstalk ID
M6ACROT03187
 [1]
m6A modification HDAC9 HDAC9 METTL3 Methylation : m6A sites Direct Enhancement Histone modification H4K12ac HDAC9 DUSP9
m6A Modification:
m6A Regulator Methyltransferase-like 3 (METTL3) WRITER
 Regulator Info 
m6A Target Histone deacetylase 9 (HDAC9)
 Targert Gene 
Epigenetic Regulation that have Cross-talk with This m6A Modification:
Epigenetic Regulation Type Histone modification (HistMod)
Epigenetic Regulator Histone deacetylase 9 (HDAC9) ERASER View Details
Regulated Target Histone H4 lysine 12 acetylation (H4K12ac) View Details
Downstream Gene DUSP9 View Details
Crosstalk Relationship m6A  →  Histone modification Enhancement
Crosstalk Mechanism m6A modification impacts directly histone modification through modulating the expression level of histone-associated enzymes
Crosstalk Summary PM exposure increased the expression of histone deacetylase 9 (Histone deacetylase 9 (HDAC9)) in human bronchial epithelial cells and mouse airway epithelium through the METTL3/m6A methylation/IGF2BP3 pathway. HDAC9 modulated the deacetylation of Histone H4 lysine 12 acetylation (H4K12ac) in the promoter region of DUSP9 to repress the expression of DUSP9 and resulting in the activation of MAPK signaling pathway
Responsed Disease Acute laryngitis or tracheitis ICD-11: CA05
 Disease Info 
Full List of Potential Compound(s) Related to This m6A-centered Crosstalk
Dual specificity protein phosphatase 9 (DUSP9) 4 Compound(s) Regulating the Target Click to Show/Hide the Full List
 Compound Name ISIS 103473 Investigative [2]
External Link
TTD: D07HIJ
 Compound Name ISIS 103471 Investigative [2]
External Link
TTD: D07RVX
 Compound Name ISIS 103489 Investigative [2]
External Link
TTD: D0Q3KN
 Compound Name ISIS 103486 Investigative [2]
External Link
TTD: D0S4BJ
Histone deacetylase 9 (HDAC9) 8 Compound(s) Regulating the Target Click to Show/Hide the Full List
 Compound Name PMID29671355-Compound-73 Patented [3]
MOA Inhibitor
Activity IC50 = 1000 nM
External Link
CID: 124194015
TTD: D0T7OQ
 Compound Name PMID29671355-Compound-45a Patented [3]
MOA Inhibitor
Activity IC50 = 40 nM
External Link
CID: 86302836
TTD: D0YN2T
 Compound Name PMID29671355-Compound-31 Patented [3]
MOA Inhibitor
Activity IC50 > 15000 nM
External Link
CID: 90479372
TTD: D0DI9S
DrugBank: DB14979
 Compound Name PMID29671355-Compound-21 Patented [3]
MOA Inhibitor
Activity IC50 = 10300 nM
External Link
CID: 86295624
TTD: D0LP1K
 Compound Name PMID29671355-Compound-62 Patented [3]
MOA Inhibitor
Activity IC50 = 100 to 500 nM
External Link
TTD: D07WAT
 Compound Name PMID29671355-Compound-43 Patented [3]
MOA Inhibitor
Activity IC50 > 100000 nM
External Link
CID: 118515590
TTD: D0BP8I
 Compound Name PMID29671355-Compound-25 Patented [3]
MOA Inhibitor
Activity IC50 = 1410 nM
External Link
CID: 126569528
TTD: D0RA0D
 Compound Name TMP269 Investigative [4]
Synonyms
TMFO1; compound 1 [PMID: 23524983]; TMP-269; TMP 269
    Click to Show/Hide
MOA Inhibitor
Activity IC50 = 19.4 nM
External Link
CID: 53344908
TTD: D0R7JA
CA05: Acute laryngitis or tracheitis 2 Compound(s) Regulating the Disease Click to Show/Hide the Full List
 Compound Name MMI-0100 Phase 1 [5]
Synonyms
Peptide MAPKAPK2 inhibitors (inflammation/scarring/fibrosis), Moerae Matrix; Peptide MK2 inhibitors (inflammation/scarring/fibrosis), Moerae Matrix
    Click to Show/Hide
External Link
TTD: D0S7NS
 Compound Name SU5614 Terminated [6]
Synonyms
SU 5614; SU-5614; (3Z)-5-chloro-3-[(3,5-dimethyl-1H-pyrrol-2-yl)methylidene]-1H-indol-2-one; 5-Chloro-3-[(3,5-dimethylpyrrol-2-yl)methylene]-2-indolinone
    Click to Show/Hide
External Link
CID: 6536806
TTD: D01MIP
References
Ref 1 m(6)A-mediated HDAC9 upregulation promotes particulate matter-induced airway inflammation via epigenetic control of DUSP9-MAPK axis and acts as an inhaled nanotherapeutic target. J Hazard Mater. 2024 Sep 15;477:135093. doi: 10.1016/j.jhazmat.2024.135093. Epub 2024 Jul 6.
Ref 2 US patent application no. 6,566,133, Antisense inhibition of dual specific phosphatase 9 expression.
Ref 3 HDAC inhibitors: a 2013-2017 patent survey. Expert Opin Ther Pat. 2018 Apr 19:1-17. doi: 10.1080/13543776.2018.1459568. Online ahead of print.
Ref 4 Selective class IIa histone deacetylase inhibition via a nonchelating zinc-binding group. Nat Chem Biol. 2013 May;9(5):319-25. doi: 10.1038/nchembio.1223. Epub 2013 Mar 24.
Ref 5 ClinicalTrials.gov (NCT02515396) Phase 1a Study in Healthy Smokers to Investigate the Effect With MMI-0100 on Airway Inflammation in Induced Sputum After Challenge With Inhaled Lipopolysaccharide (LPS). U.S. National Institutes of Health.
Ref 6 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800014776)